Page 27 - Solid Tumors News Today

Gilead Sciences announces partial clinical hold on phase 3 trial of magrolimab for the treatment of acute myeloid leukemia.

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.

Marwan G. Fakih, MD, discusses the main objective and design of the observational BASECAMP-1 study and how it functions alongside the phase 1/2 EVEREST-1 study in patients with solid tumors.

Lisata Therapeutics, Inc. (NASDAQ:LSTA) Q2 2023 Earnings Call Transcript August 17, 2023 Operator: Welcome to the Lisata Therapeutics Second Quarter 2023 Financial Results and Business Update Conference Call. Currently, all participants are in a listen-only mode. Following managements’ prepared remarks, we will hold a question-and-answer session. [Operator Instructions] As a reminder, the call is being […]

The combination regimen showed positive progression-free survival results among patients with HER2-positive breast cancer in the phase 3 HER2CLIMB-02 trial, but overall survival data have yet to mature.

Seagen Inc. today announced that the Phase 3 HER2CLIMB-02 clinical trial of TUKYSA® in combination with the antibody-drug conjugate ado-trastuzumab emtansine met its primary endpoint of... -Today at 08:06 am- MarketScreener

BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN) today announced that the Phase 3 HER2CLIMB-02 clinical trial of TUKYSA® (tucatinib) in combination with the antibody-drug conjugate ado-trastuzumab emtansine (Kadcyla®) met its primary endpoint of progression-free survival (PFS). Patients in the trial had u...

Treatment with the long-acting interleukin-2 superkine led to durable tumor control and no dose-limiting toxicities in patients with advanced solid tumors, according to data from the dose-escalation portion of the phase 1/2 ABILITY-1 trial.

– Enrollment continues globally in multiple clinical studies of vepdegestrant , including VERITAC-2 2L Phase 3 trial and study lead-in for the VERITAC-3 1L Phase 3 trial, both in ER+/HER2-...

– Petosemtamab granted Fast Track Designation for the treatment of patients with recurrent or metastatic head & neck squamous cell carcinoma – Phase 3 trial of petosemtamab monotherapy in...